可穿戴设备联合八段锦在代谢综合征运动管理的随机对照研究

注册号:

Registration number:

ITMCTR2200005860

最近更新日期:

Date of Last Refreshed on:

2022-04-14

注册时间:

Date of Registration:

2022-04-14

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

可穿戴设备联合八段锦在代谢综合征运动管理的随机对照研究

Public title:

A randomized controlled study of wearable devices combined with Baduanjin in the management of movement in metabolic syndrome

注册题目简写:

English Acronym:

研究课题的正式科学名称:

可穿戴设备联合八段锦在代谢综合征运动管理的随机对照研究

Scientific title:

A randomized controlled study of wearable devices combined with Baduanjin in the management of movement in metabolic syndrome

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200058684 ; ChiMCTR2200005860

申请注册联系人:

李安香

研究负责人:

刘振杰

Applicant:

Anxiang Li

Study leader:

Zhenjie Liu

申请注册联系人电话:

Applicant telephone:

13435683615

研究负责人电话:

Study leader's telephone:

13711758166

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

928710497@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zhenjl@139.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广州市荔湾区芳村花地涌岸街36号

研究负责人通讯地址:

广州市荔湾区芳村花地涌岸街36号

Applicant address:

36 Huadi Yongan Street,Fangcun,Liwan District,Guangzhou,Guangdong

Study leader's address:

36 Huadi Yongan Street,Fangcun,Liwan District,Guangzhou,Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广东省中医院芳村医院

Applicant's institution:

Fangcun Hospital,Guangdong Provincial Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

BF2022-044-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Hospital of traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022/3/18 0:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Xiaoyan Li

伦理委员会联系地址:

广州市越秀区大德路111号

Contact Address of the ethic committee:

111 Date Road,Yuexiu District,Guangzhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广东省中医院

Primary sponsor:

Guangdong Provincial Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

广州市越秀区大德路111号

Primary sponsor's address:

111 Date Road,Yuexiu District,Guangzhou

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院

具体地址:

广州市越秀区大德路111号

Institution
hospital:

Guangdong Provincial Hospital of Traditional Chinese Medicine

Address:

111 Date Road,Yuexiu District,Guangzhou

经费或物资来源:

国家重点研发项目

Source(s) of funding:

National key R & D projects

研究疾病:

代谢综合征

研究疾病代码:

Target disease:

Metabolic syndrome

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1.探索可穿戴设备联合八段锦在代谢综合征患者运动管理中的应用效果。 2.分析可穿戴设备在代谢综合征人群日常监测与管理应用中的可行性; 3.为形成可行有效的代谢综合征综合干预方案奠定基础。

Objectives of Study:

1.To explore the effectiveness of wearable devices combined with Badaanjin in the exercise management of patients with metabolic syndrome. 2.To analyze the feasibility of wearable devices in the application of daily monitoring and management of the metabolic syndrome population. 3.To lay the foundation for the formation of a feasible and effective comprehensive intervention program for metabolic syndrome.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①年龄在18-70周岁之间; ②广东省中医院内分泌科门诊及病房的患者; ③符合代谢综合征诊断的患者;且BMI≥24kg/m2。 ④签署知情同意书者。

Inclusion criteria

①Age between 18 and 70 years old. ②Patients in the outpatient clinic and ward of the Department of Endocrinology of Guangdong Provincial Hospital of Traditional Chinese Medicine. ③Patients who meet the diagnosis of metabolic syndrome; and BMI ≥ 24 kg/m2 . ④Those who signed the informed consent form.

排除标准:

①严重心肝肾功能不全(血肌酐清除率<30ml/min,丙氨酸氨基转移酶≥2.5倍正常上限,总胆红素≥1.5倍正常上限;慢性心功能不全,心功能分级III级和以上); ②严重心肌缺血、严重高血压病、血糖不稳定等不宜运动者; ③中风后遗症、关节肌肉疾病、腰椎疾病等不能配合运动者;; ④继发性血脂、血压、血糖异常; ⑤1 型糖尿病; ⑥甲亢或甲减; ⑦服用糖皮质激素、避孕药、减肥药等影响体重药物; ⑧不能理解研究内容、难以接受研究方案者。

Exclusion criteria:

① Severe cardiac, hepatic and renal insufficiency (blood creatinine clearance <30 ml/min, alanine aminotransferase ≥2.5 times the upper limit of normal, total bilirubin ≥1.5 times the upper limit of normal; chronic cardiac insufficiency, cardiac function class III and above). ②Those who are not suitable for exercise such as severe myocardial ischemia, severe hypertensive disease and unstable blood sugar. ③Those who cannot cooperate with exercise such as post-stroke, joint and muscle diseases, lumbar spine diseases, etc. ④Secondary lipid, blood pressure and glucose abnormalities. ⑤Type 1 diabetes. ⑥Hyperthyroidism or hypothyroidism. ⑦Taking weight-impacting drugs such as glucocorticoids, birth control pills and diet pills. ⑧Those who cannot understand the content of the study and have difficulty accepting the research protocol.

研究实施时间:

Study execute time:

From 2022-04-01

To      2022-12-31

征募观察对象时间:

Recruiting time:

From 2022-04-01

To      2022-12-31

干预措施:

Interventions:

组别:

对照组

样本量:

20

Group:

control group

Sample size:

干预措施:

干预措施代码:

Intervention:

no intervention

Intervention code:

组别:

治疗组2

样本量:

20

Group:

Treatment group

Sample size:

干预措施:

可穿戴设备联合八段锦

干预措施代码:

Intervention:

Wearable devices combined with Baduanjin

Intervention code:

组别:

治疗组1

样本量:

20

Group:

Treatment group

Sample size:

干预措施:

可穿戴设备

干预措施代码:

Intervention:

Wearable devices

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院

单位级别:

三级甲等

Institution/hospital:

Guangdong Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

体重指数

指标类型:

次要指标

Outcome:

BMI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血糖

指标类型:

次要指标

Outcome:

Blood glucose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医症候评分

指标类型:

次要指标

Outcome:

TCM symptom score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

运动依从性

指标类型:

次要指标

Outcome:

Exercise adherence

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

Blood pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

EQ-5D健康指数量表

指标类型:

次要指标

Outcome:

EQ-5D health index scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体脂率

指标类型:

次要指标

Outcome:

Body fat rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胰岛素抵抗指数

指标类型:

主要指标

Outcome:

HOMA-IR

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血脂

指标类型:

次要指标

Outcome:

Blood fat

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 70
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

完全随机化分组,采用随机数字表的方法

Randomization Procedure (please state who generates the random number sequence and by what method):

Completely randomized grouping;The method of random number table

盲法:

不设盲法

Blinding:

no blinding

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

暂无

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统